Connectome Raises €1.7M for Brain Health Monitoring

NeuroTech innovator Connectome has successfully raised approximately €1.7 million ( $2 million) in a pre-Seed funding round, signaling a significant push to revolutionize personalized brain health monitoring. The investment, spearheaded by Redstone, saw robust participation from prominent early-stage venture capital firms including Concept Ventures and Octopus. A cohort of strategic investors and seasoned angel investors from across Switzerland, the UK, Europe, and the US also contributed to the round, which notably includes €103.6k ($120k) in non-dilutive public innovation funding.

This capital infusion is earmarked to scale Connectome's proprietary technology, which aims to provide a more nuanced and individualized understanding of cognitive function. The company is addressing a critical gap in the health tech landscape, where advancements in physical health tracking have far outpaced our ability to objectively measure and safeguard brain health. As CEO Lucas Scherdel articulated, the escalating prevalence of burnout, brain fog, and attention deficits, particularly among younger demographics, underscores the urgent need for accessible tools to detect early cognitive changes and promote long-term brain resilience.

Founded in 2024 by neuroscientists Lucas Scherdel and Dr. Rufus Mitchell-Heggs, Connectome leverages cutting-edge research, including work conducted with Imperial College London. Their platform is built upon the findings of studies like LUCID, which demonstrated that everyday behaviors leave distinct, quantifiable signatures in brain activity. This allows for the measurement of brain function in real-world settings, moving beyond the limitations of static, isolated assessments.

The core innovation lies in Connectome's approach to longitudinal brain measurement. Instead of relying on single data points, the platform monitors brain activity repeatedly over time to establish a personalized baseline. By integrating this neural data with daily lifestyle factors such as sleep patterns, physical activity, and cognitive load, Connectome aims to connect observed brain changes to their real-world drivers. This personalized methodology holds promise for applications ranging from neurodevelopmental support to early detection of neurodegenerative conditions, offering insights long before traditional clinical markers become apparent.

The implications for the burgeoning digital health and neurotech markets are substantial. With the global digital health market projected to reach hundreds of billions of dollars in the coming years, solutions that offer objective, personalized health insights are in high demand. Connectome's focus on cognitive health, a segment increasingly recognized for its importance in overall well-being and productivity, positions it strategically within this growth trajectory. The company emphasizes that its platform is designed to augment, not replace, clinical judgment, serving as a powerful tool for research, monitoring, and informed decision-making.

Dr. Rufus Mitchell-Heggs, the company's CSO, likens healthy brain blood flow to a dynamic 'neighborhood' rather than a fixed point. The LUCID study aims to map this healthy variation, providing a reference for identifying deviations that may indicate the onset of neurological disease or cognitive impairment. By tracking these shifts over time and correlating them with subjective reports, Connectome seeks to unravel the underlying mechanisms driving cognitive changes, paving the way for future diagnostic and therapeutic advancements.